Dialyse aktuell 2020; 24(02): 61-67
DOI: 10.1055/a-1022-7939
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Hämodialyse

Was ist bei der Entscheidung bzgl. des Nierenersatzverfahrens zu beachten?
Joachim Beige
1   KfH Nierenzentrum und Abteilung Nephrologie, Klinikum Sankt Georg, Leipzig
2   Martin-Luther-Universität Halle/Wittenberg
› Author Affiliations
Further Information

Publication History

Publication Date:
13 March 2020 (online)

ZUSAMMENFASSUNG

Die Wahl des Dialyseverfahrens erfolgt auf der Basis eines umfassenden Aufklärungsgesprächs zwischen Arzt und Patienten über die individuellen Merkmale der einzelnen Verfahren und ihrer Eignung für den Patienten. Das medizinisch beste Nierenersatzverfahren ist die Nierentransplantation, die aus verschiedenen Gründen jedoch nicht immer durchgeführt werden kann. Zwischen den beiden apparativen Dialyseverfahren Hämo- (HD) und Peritonealdialyse (PD) gibt es keine größeren, evidenzgesicherten Unterschiede bzgl. Morbidität und Mortalität, sodass hier neben einigen Ein- und Ausschlusskriterien die Patientenpriorität berücksichtigt werden muss. Zu den Patientenmerkmalen und -wünschen gehören die Auswirkung auf die Alltagsgestaltung, Berücksichtigung der Restdiurese und evtl. seltene Ausschlussmerkmale bei der Zugangswahl. Da die PD in den ersten Jahren nach Dialysestart einen evtl. Mortalitätsvorteil bieten könnte, macht es bei voraussichtlich langer Dialyseabhängigkeit deshalb Sinn, eine „Nierenersatzkarriere“ mit der PD zu beginnen und HD-Verfahren erst später zu nutzen.

 
  • Literatur

  • 1 Robinski M, Neumann D, Mau W. et al The Choice of Renal Replacement Therapy (CORETH) Project: Der psychosoziale Status in der Frühphase der Peritoneal- und Hämodialyse. Nieren- Hochdruckkrankheiten 2016; 45: 194-201 doi:10.5414/NHX01777
  • 2 Churchill DN. Implications of the Canada-USA (CANUSA) study of the adequacy of dialysis on peritoneal dialysis schedule. Nephrol Dial Transplant 1998; 13 (Suppl. 06) 158-163 doi:10.1093/ndt/13.suppl_6.158
  • 3 Murphy SW, Foley RN, Barrett BJ. et al Comparative mortality of hemodialysis and peritoneal dialysis in Canada. Kidney Int 2000; 57: 1720-1726 doi:10.1046/j.1523-1755.2000.00017.x
  • 4 Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9 Suppl S16-S23
  • 5 Pauly RP. Survival comparison between intensive hemodialysis and transplantation in the context of the existing literature surrounding nocturnal and short-daily hemodialysis. Nephrol Dial Transplant 2013; 28: 44-47 doi:10.1093/ndt/gfs419
  • 6 Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993; 4: 1205-1213
  • 7 Lowrie EG, Zhu X, Lew NL. Primary associates of mortality among dialysis patients: trends and reassessment of Kt/V and urea reduction ratio as outcome-based measures of dialysis dose. Am J Kidney Dis 1998; 32 (Suppl. 04) S16-S31 doi:10.1016/s0272-6386(98)70158-1
  • 8 Tentori F, Zhang J, Li Y. et al Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2012; 27: 4180-4188 doi:10.1093/ndt/gfs021
  • 9 Charra B, Chazot C, Jean G. et al Long 3 × 8 hr dialysis: a three-decade summary. J Nephrol 2003; 16 (Suppl. 07) S64-S69
  • 10 Charra B, Terrat JC, Vanel T. et al Long thrice weekly hemodialysis: the Tassin experience. Int J Artif Organs 2004; 27: 265-283 doi:10.1177/039139880402700403
  • 11 Rocco MV, Daugirdas JT, Greene T. et al FHN Trial Group. Long-term Effects of Frequent Nocturnal Hemodialysis on Mortality: The Frequent Hemodialysis Network (FHN) Nocturnal Trial. Am J Kidney Dis 2015; 66: 459-468 doi:10.1053/j.ajkd.2015.02.331
  • 12 De Alvaro F, Bajo MA, Alvarez-Ude F. et al Adequacy of peritoneal dialysis: does kt/v have the same predictive value as in HD? A multicenter study. Adv Perit Dial 1992; 8: 93-97
  • 13 Karaboyas A, Zee J, Brunelli SM. et al Dialysate Potassium, Serum Potassium, Mortality, and Arrhythmia Events in Hemodialysis: Results From the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2016; 69: 266-277 doi:10.1053/j.ajkd.2016.09.015
  • 14 Drew DA, Koo B-B, Bhadelia R, Weiner DE. et al White matter damage in maintenance hemodialysis patients: a diffusion tensor imaging study. BMC Nephrol 2017; 18: 213 doi:10.1186/s12882-017-0628-0
  • 15 Polinder-Bos HA, García DV, Kuipers J. et al Hemodialysis Induces an Acute Decline in Cerebral Blood Flow in Elderly Patients. J Am Soc Nephrol 2018; 29: 1317-1325 doi:10.1681/ASN.2017101088
  • 16 McIntyre C, Crowley L. Dying to Feel Better: The Central Role of Dialysis-Induced Tissue Hypoxia. Clin J Am Soc Nephrol 2016; 11: 549-551 doi:10.2215/CJN.01380216
  • 17 McIntyre CW, Burton JO, Selby NM. et al Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental myocardial blood flow. Clin J Am Soc Nephrol 2008; 3: 19-26 doi:10.2215/CJN.03170707
  • 18 McIntyre CW, Odudu A. Hemodialysis-associated cardiomyopathy: a newly defined disease entity. Semin Dial 2014; 27: 87-97 doi:10.1111/sdi.12197
  • 19 Breidthardt T, Burton JO, Odudu A. et al Troponin T for the detection of dialysis-induced myocardial stunning in hemodialysis patients. Clin J Am Soc Nephrol 2012; 7: 1285-1292 doi:10.2215/CJN.00460112
  • 20 Jakob SM, Ruokonen E, Vuolteenaho O. et al Splanchnic perfusion during hemodialysis: evidence for marginal tissue perfusion. Crit Care Med 2001; 29: 1393-1398 doi:10.1097/00003246-200107000-00015
  • 21 McIntyre CW, Harrison LEA, Eldehni MT. et al Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 133-141 doi:10.2215/CJN.04610510
  • 22 Vanholder R, Glorieux G, Lameire N. The other side of the coin: impact of toxin generation and nutrition on the uremic syndrome. Semin Dial 2002; 15: 311-314 doi:10.1046/j.1525-139x.2002.00076.x
  • 23 Beige J. Die Rolle von Hämodynamik und Biosignalen für eine „verträgliche“ Hämodialyse – Intradialytische Ereignisse (IME) sind ein entscheidender Einflussfaktor. Dialyse aktuell 2018; 22: 350-359 doi:10.1055/a-0733-2855
  • 24 Pelosi G, Emdin M, Carpeggiani C. et al Impaired sympathetic response before intradialytic hypotension: a study based on spectral analysis of heart rate and pressure variability. Clin Sci (Lond) 1999; 96: 23-31
  • 25 Flythe JE, Hilliard T, Castillo G. et al Symptom Prioritization among Adults Receiving In-Center Hemodialysis: A Mixed Methods Study. Clin J Am Soc Nephrol 2018; 13: 735-745 doi:10.2215/CJN.10850917
  • 26 Ronco C, Brendolan A, Milan M. et al Impact of biofeedback-induced cardiovascular stability on hemodialysis tolerance and efficiency. Kidney Int 2000; 58: 800-808 doi:10.1046/j.1523-1755.2000.00229.x
  • 27 Leber HW, Wizemann V, Goubeaud G. et al Hemodiafiltration: a new alternative to hemofiltration and conventional hemodialysis. Artif Organs 1978; 2: 150-153
  • 28 Koda Y, Aoike I, Hasegawa S. et al Feasibility of intermittent back-filtrate infusion hemodiafiltration to reduce intradialytic hypotension in patients with cardiovascular instability: a pilot study. Clin Exp Nephrol 2017; 21: 324-332 doi:10.1007/s10157-016-1270-z
  • 29 Lindley E. Merits and limitations of the measurement of relative blood volume changes during haemodialysis. J Ren Care 2007; 33: 89-90 doi:10.1111/j.1755-6686.2007.tb00047.x
  • 30 Beige J, Sone J, Sharma AM. et al Computational analysis of blood volume curves and risk of intradialytic morbid events in hemodialysis. Kidney Int 2000; 58: 1805-1809 doi:10.1046/j.1523-1755.2000.00343.x
  • 31 Franssen CF, Dasselaar JJ, Sytsma P. et al Automatic feedback control of relative blood volume changes during hemodialysis improves blood pressure stability during and after dialysis. Hemodial Int 2005; 9: 383-392 doi:10.1111/j.1492-7535.2005.01157.x
  • 32 Kron S, Schneditz D, Leimbach T. et al Determination of the critical absolute blood volume for intradialytic morbid events. Hemodial Int 2016; 20: 321-326 doi:10.1111/hdi.12375
  • 33 Lee KG, Chong TT, Goh N. et al Outcomes of arteriovenous fistula creation, effect of preoperative vein mapping and predictors of fistula success in incident haemodialysis patients: A single-centre experience. Nephrol Carlton Vic 2017; 22: 382-387 doi:10.1111/nep.12788
  • 34 Lauvao LS, Ihnat DM, Goshima KR. et al Vein diameter is the major predictor of fistula maturation. J Vasc Surg 2009; 49: 1499-1504 doi:10.1016/j.jvs.2009.02.018
  • 35 Cooper BA, Branley P, Bulfone L. et al The Initiating Dialysis Early and Late (IDEAL) study: study rationale and design. Perit Dial Int 2004; 24: 176-181
  • 36 Dolovich J, Marshall CP, Smith EK. et al Allergy to ethylene oxide in chronic hemodialysis patients. Artif Organs 1984; 8: 334-337
  • 37 Marshall C, Shimizu A, Smith EK, Dolovich J. Ethylene oxide allergy in a dialysis center: prevalence in hemodialysis and peritoneal dialysis populations. Clin Nephrol 1984; 21: 346-349
  • 38 Dolovich J, Bell B. Allergy to a product(s) of ethylene oxide gas: demonstration of IgE and IgG antibodies and hapten specificity. J Allergy Clin Immunol 1978; 62: 30-32
  • 39 Grammer LC, Roberts M, Wiggins CA. et al A comparison of cutaneous testing and ELISA testing for assessing reactivity to ethylene oxide-human serum albumin in hemodialysis patients with anaphylactic reactions. J Allergy Clin Immunol 1991; 87: 674-676
  • 40 Grammer LC, Patterson R. IgE against ethylene oxide-altered human serum albumin (ETO-HSA) as an etiologic agent in allergic reactions of hemodialysis patients. Artif Organs 1987; 11: 97-99
  • 41 Bacelar Marques ID, Pinheiro KF, de Freitas do Carmo LP. et al Anaphylactic reaction induced by a polysulfone/polyvinylpyrrolidone membrane in the 10th session of hemodialysis with the same dialyzer. Hemodial Int 2011; 15: 399-403 doi:10.1111/j.1542-4758.2011.00553.x
  • 42 Beige JH, Rüssmann D. Polysulfon Intolerance in Hemodialysis. Unpublished 2019 doi:10.13140/rg.2.2.33693.87520
  • 43 Rodriguez-Sanz A, Sanchez-Villanueva R, Dominguez-Ortega J. et al Mechanisms Involved in Hypersensitivity Reactions to Polysulfone Hemodialysis Membranes. Artif Organs 2017; 41: E285-E295 doi:10.1111/aor.12954
  • 44 Gemeinsamer Bundesausschuss Jahresbericht G-BA für 2016 Jahresbericht 2016 zur Qualität in der Dialyse. 31.03.2017. Im Internet https://www.g-ba.de/downloads/39-261-3024/2017-07-20_QSD-RL_MNC-Jahresbericht-2016.pdf Stand: 31.01.2020
  • 45 Robinski M, Mau W, Wienke A, Girndt M. The Choice of Renal Replacement Therapy (CORETH) project: dialysis patients’ psychosocial characteristics and treatment satisfaction. Nephrol Dial Transplant 2017; 32: 315-324 doi:10.1093/ndt/gfv464
  • 46 Weinhandl ED, Liu J, Gilbertson DT. et al Survival in Daily Home Hemodialysis and Matched Thrice-Weekly In-Center Hemodialysis Patients. J Am Soc Nephrol 2012; 23: 895-904 doi:10.1681/ASN.2011080761
  • 47 Beige J. Deutsche Gesellschaft für Nephrologie. Information zur Durchführung spezifischer immuntoxikologischer Tests beim Verdacht auf Polysulfonallergie 2019 Im Internet https://www.dgfn.eu/nachrichtenleser-195/unvertraeglichkeit-von-dialysematerialien.html Stand: 31.01.2020